Sellas Life Sciences Group Inc (SLS)

$1.23

+0.07

(+6.03%)

Market is closed - opens 8 PM, 11 Nov 2024

Performance

  • $1.16
    $1.24
    $1.23
    downward going graph

    5.69%

    Downside

    Day's Volatility :6.45%

    Upside

    0.81%

    downward going graph
  • $0.50
    $1.72
    $1.23
    downward going graph

    59.46%

    Downside

    52 Weeks Volatility :71.01%

    Upside

    28.49%

    downward going graph

Returns

PeriodSellas Life Sciences Group IncIndex (Russel 2000)
3 Months
1.65%
0.0%
6 Months
-4.65%
0.0%
1 Year
35.18%
0.0%
3 Years
-86.79%
-27.1%

Highlights

Market Capitalization
74.6M
Book Value
$0.05
Earnings Per Share (EPS)
-0.9
Wall Street Target Price
5.83
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-129.15%
Return On Equity TTM
-888.06%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-82.5%
Gross Profit TTM
900.0K
Diluted Eps TTM
-0.9
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.57
EPS Estimate Next Year
-0.43
EPS Estimate Current Quarter
-0.16
EPS Estimate Next Quarter
-0.15

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Sellas Life Sciences Group Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 373.98%

Current $1.23
Target $5.83

Technicals Summary

Sell

Neutral

Buy

Sellas Life Sciences Group Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sellas Life Sciences Group Inc
Sellas Life Sciences Group Inc
3.36%
-4.65%
35.18%
-86.79%
-78.23%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.16%
-14.42%
3.52%
34.42%
140.62%
Biontech Se
Biontech Se
-5.81%
20.18%
11.4%
-51.12%
460.49%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
2.41%
83.28%
68.63%
50.84%
200.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.42%
23.33%
40.2%
170.42%
155.94%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sellas Life Sciences Group Inc
Sellas Life Sciences Group Inc
NA
NA
NA
-0.57
-8.88
-1.29
NA
0.05
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.41
20.41
1.2
44.89
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.1
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-1.87
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.27
0.19
-0.03
0.13
NA
60.66
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sellas Life Sciences Group Inc
Sellas Life Sciences Group Inc
Buy
$74.6M
-78.23%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.6B
140.62%
20.41
33.61%
Biontech Se
Biontech Se
Buy
$25.9B
460.49%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$35.1B
200.09%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.9B
155.94%
32.84
-4.51%

Insights on Sellas Life Sciences Group Inc

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.6% return, outperforming this stock by 33.4%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 50.8% return, outperforming this stock by 137.6%

Institutional Holdings

  • Vanguard Group Inc

    2.78%
  • Geode Capital Management, LLC

    0.80%
  • BlackRock Inc

    0.67%
  • Opus Capital Group LLC

    0.34%
  • Equitable Holdings Inc

    0.33%
  • Diametric Capital, LP

    0.24%

Company Information

σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.

Organization
Sellas Life Sciences Group Inc
Employees
16
CEO
Dr. Angelos M. Stergiou M.D., ScD h.c.
Industry
Health Technology

FAQs